Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17869475 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2AOGAKCNMA1 | |
| SCHEMBL17869064 | 0.84 | ACSL1 (0.43) | OGAFAAH | |
| SCHEMBL17869069 | 0.84 | ACSL1 (0.43) | OGAFAAH | |
| SCHEMBL2469600 | 0.82 | EPHX2 (0.47) | KCNMA1ALDH1A1KDM4EMAPTAVPR1A | |
| SCHEMBL30356808 | 0.82 | EPHX2 (0.47) | KCNMA1ALDH1A1KDM4EMAPTAVPR1A | |
| SCHEMBL2474542 | 0.82 | EPHX2 (0.47) | KCNMA1ALDH1A1KDM4EMAPTAVPR1A | |
| SCHEMBL2469597 | 0.82 | EPHX2 (0.47) | KCNMA1ALDH1A1KDM4EMAPTAVPR1A | |
| SCHEMBL2472706 | 0.78 | HCRTR1 (0.44) | ALDH1A1AXLMERTKQPCTQPCTL | |
| SCHEMBL17869437 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2472710 | 0.78 | HCRTR1 (0.44) | ALDH1A1AXLMERTKQPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-107406451-B | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3240791-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885MEN1 1492/4885KMT2A 2158/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885MEN1 1492/4885KMT2A 2158/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885MEN1 1492/4885KMT2A 2158/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885MEN1 1492/4885KMT2A 2158/4885 |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1753/4885MEN1 1380/4885KMT2A 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.